Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Has announcements × melflufen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 9 trastuzumab deruxtecan 6 Cyclophosphamide 4 zanubrutinib 3 trametinib 3 tisagenlecleucel 3 nilotinib 3 fludarabine 3 dabrafenib 3 Dexamethasone 3 tucatinib 2 selinexor 2 pemigatinib 2 entrectinib 2 enfortumab vedotin 2 daratumumab 2 blinatumomab 2 belzutifan 2 axicabtagene ciloleucel 2 atezolizumab 2 Vincristine 2 Trastuzumab 2 TIC10 compound 2 Specimen Handling 2 Prednisone 2 Lenalidomide 2 Ipilimumab 2 Cytarabine 2 Cisplatin 2 Carboplatin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02963493 2022-11-22

HORIZON

Oncopeptides AB

Phase 2 Completed

157 enrolled 26 charts 1 FDA

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡